<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72080">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765842</url>
  </required_header>
  <id_info>
    <org_study_id>RITULUP</org_study_id>
    <nct_id>NCT01765842</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy</brief_title>
  <acronym>RITULUP</acronym>
  <official_title>Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy Resistant to Conventional Treatments.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus
      Nephropathy Resistant to Conventional Treatments
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, open, controlled, multicenter, clinical trial in patients with lupus nephritis
      previously treated with cyclophosphamide and mycophenolate. These patient can not have
      received Rituximab in the previous year. The number of patients estimated to reach
      statistical significance is 18 in each arm, a total sample size of 32 patients is needed.

      The hypothesis is that the alternative procedure (a second cycle of Rituximab)will reduce
      the relapse rate of lupus nephritis and the consequent deterioration of renal function.
      Besides it will reduce health care expenses(hospitalization, medication, hemodialysis and
      renal transplantation).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of complete or partial response in lupus nephritis</measure>
    <time_frame>Assessment  at 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response defined as:
Glomerular Filtration Rate (GFR)≥ 60, 73 m2 (or decline to baseline or
± 15% of baseline in those with GFR &lt;60 ml/min/1, 73m2).
Proteinuria ≤ 0.5 g/24 hours.
Inactive urine sediment (red cells, white cells, red cell casts according to local laboratory ranges).
Serum albumin&gt; 3 g / dl
Partial response defined as:
In patients with proteinuria ≥ 3.5 gr/24 h , decreased proteinuria &lt;3.5 gr/24 hours.
In patients with baseline proteinuria &lt;3.5 gr/24 hours, reduced proteinuria&gt; 50% of baseline.
In both situations, stabilization (± 25%) or reduce of the Glomerular Filtration Rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>24 months of follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of patients achieving a stabilization of renal function (Glomerular filtration rate of ± 25% over baseline or serum creatinine within normal range)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>24 months of follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of adverse events, serious adverse events and adverse events that led to the interruption of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication</measure>
    <time_frame>24 months of follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Need for immunosuppressive treatment added to the experimental pattern:
- Mycophenolate
- Azathioprine
- Methotrexate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>24 months of follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Improvements in Selena-SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) score results</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Rituximab (1 cycle)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 cycle of Rituximab (4 i.v. infusions):
Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab (2 cycles)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A second cycle of Rituximab
First cycle of Rituximab (4 i.v. infusions):
Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2
Second cycle of Rituximab (4 i.v. infusions, 6 months later)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Only one cycle of rituximab will be administered in this arm.</description>
    <arm_group_label>Rituximab (1 cycle)</arm_group_label>
    <arm_group_label>Rituximab (2 cycles)</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both men and women between 18 and 70 years.

          -  Patient  with active lupus nephritis,  previously treated with cyclophosphamide and
             mycophenolate (sodium or mofetil), who have not received rituximab in the previous
             year.

          -  Women in childbearing age must have a pregnancy test in serum or urine negative and
             should use a contraceptive method suitable since at least 14 days prior to their
             inclusion in the study and up to 6 months after the last dose of the medication of
             the test.

          -  Informed consent form signed.

        Exclusion Criteria:

          -  Patients treated with rituximab in the previous years

          -  Active/sepsis serious infections

          -  Renal biopsy showing interstitial fibrosis and/or glomerular over 75%.

          -  Known neoplasia

          -  Heart failure with  III/IV functional class

          -  Pregnancy

          -  Nursing

          -  Known anaphylaxis to the product

          -  History of hepatitis c

          -  History of tuberculosis

          -  Cardiovascular disease or uncontrolled hypertension

          -  Chronic hepatitis B

          -  Serious Cytopenia (granulocytes &lt; 500/mm3, further &lt; 10000/mm3)

          -  Immunodeficiency (CVI, immunoglobulins deficiency)

          -  Infection with HIV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María Jesús Castillo Palma, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Virgen del Rocío Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María Jesús Castillo Palma, MD, PhD</last_name>
    <phone>00349550134</phone>
    <email>MAJECA@telefonica.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clara M. Rosso Fernández, MD</last_name>
    <phone>00349550134</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Cecilio Hospital</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norberto Ortego Centeno, MD, PhD</last_name>
      <phone>0034958023559</phone>
      <email>nortego@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Norberto Ortego Centeno, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juan Ramón Jiménez Hospital</name>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignacio Martín Suarez, MD, PhD</last_name>
      <phone>0034959016131</phone>
      <email>imsuarez@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Ignacio Martín Suarez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carlos Haya Hospital</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrique Ramón Garrido, MD, PhD</last_name>
      <phone>0034951290013</phone>
      <email>ederamongm2@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Enrique Ramón Garrido, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Ramón Garrido, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virgen del Rocío, Hospital</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara M. Rosso Fernández, MD</last_name>
      <phone>0034955013414</phone>
      <email>claram.rosso.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>María Jesús Castillo Palma, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 8, 2013</lastchanged_date>
  <firstreceived_date>January 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus Nephritis</keyword>
  <keyword>remission</keyword>
  <keyword>immunosuppressive treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
